1017 related articles for article (PubMed ID: 32203403)
1. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Salas A; Hernandez-Rocha C; Duijvestein M; Faubion W; McGovern D; Vermeire S; Vetrano S; Vande Casteele N
Nat Rev Gastroenterol Hepatol; 2020 Jun; 17(6):323-337. PubMed ID: 32203403
[TBL] [Abstract][Full Text] [Related]
2. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M; Salem M; Pedersen J; Nielsen OH
Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.
Cordes F; Foell D; Ding JN; Varga G; Bettenworth D
World J Gastroenterol; 2020 Jul; 26(28):4055-4075. PubMed ID: 32821070
[TBL] [Abstract][Full Text] [Related]
4. Targeting JAK-STAT signal transduction in IBD.
Soendergaard C; Bergenheim FH; Bjerrum JT; Nielsen OH
Pharmacol Ther; 2018 Dec; 192():100-111. PubMed ID: 30048708
[TBL] [Abstract][Full Text] [Related]
5. Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models.
Moon SY; Kim KD; Yoo J; Lee JH; Hwangbo C
Molecules; 2021 May; 26(9):. PubMed ID: 34068714
[TBL] [Abstract][Full Text] [Related]
6. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
[TBL] [Abstract][Full Text] [Related]
7. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
8. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
[TBL] [Abstract][Full Text] [Related]
9. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
Flamant M; Rigaill J; Paul S; Roblin X
Drugs; 2017 Jul; 77(10):1057-1068. PubMed ID: 28523588
[TBL] [Abstract][Full Text] [Related]
10. Impaired IFN-γ-dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients.
Cordes F; Lenker E; Weinhage T; Spille LJ; Bettenworth D; Varga G; Schmidt HH; Foell D
Inflamm Bowel Dis; 2021 May; 27(6):887-901. PubMed ID: 33165509
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
Danese S; Grisham M; Hodge J; Telliez JB
Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
[TBL] [Abstract][Full Text] [Related]
12. Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors.
Garrido-Trigo A; Salas A
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S713-S724. PubMed ID: 32083640
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
14. JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease.
Macaluso FS; Rodríguez-Lago I
Curr Drug Metab; 2020; 21(4):247-255. PubMed ID: 32156234
[TBL] [Abstract][Full Text] [Related]
15. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.
Nakase H
Immunol Med; 2023 Sep; 46(3):121-130. PubMed ID: 37036140
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibition in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase/signal transducer and activator of transcription pathways in spondyloarthritis.
Raychaudhuri SK; Raychaudhuri SP
Curr Opin Rheumatol; 2017 Jul; 29(4):311-316. PubMed ID: 28394822
[TBL] [Abstract][Full Text] [Related]
18. JAK inhibitors for asthma.
Georas SN; Donohue P; Connolly M; Wechsler ME
J Allergy Clin Immunol; 2021 Oct; 148(4):953-963. PubMed ID: 34625142
[TBL] [Abstract][Full Text] [Related]
19. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
[TBL] [Abstract][Full Text] [Related]
20. JAK-STAT signaling pathway in non-infectious uveitis.
Su Y; Tao T; Liu X; Su W
Biochem Pharmacol; 2022 Oct; 204():115236. PubMed ID: 36041544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]